Last reviewed · How we verify
DA-8159
DA-8159 is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
DA-8159 is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.
At a glance
| Generic name | DA-8159 |
|---|---|
| Sponsor | Dong-A PharmTech Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, DA-8159 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
- A Extension Study of Udenafil in Adolescents (PHASE3)
- Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 (PHASE3)
- Evaluation of Fontan-associated Hepatic Stiffness and the Efficacy of Udenafil in Reducing Liver Stiffness (PHASE3)
- Fontan Udenafil Exercise Longitudinal Assessment Trial (PHASE3)
- Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents (PHASE1, PHASE2)
- A Study Of The Evaluation Of Patients Opulation With Erectile Dysfunction, Treated With Sildenafil
- The Efficacy and Safety of Udenafil in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy (PHASE4)
- Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DA-8159 CI brief — competitive landscape report
- DA-8159 updates RSS · CI watch RSS
- Dong-A PharmTech Co., Ltd. portfolio CI